Search for: "MedImmune, Inc. v. Genentech, Inc." Results 1 - 20 of 153
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
24 Feb 2022, 6:12 pm by Dennis Crouch
  This question ties the case directly to MedImmune, Inc. v. [read post]
20 Dec 2021, 8:42 am by Dennis Crouch
Hazeltine Research, Inc., 401 U.S. 321 (1971) (antitrust – patent pools – waiver of defenses); MedImmune, Inc. v. [read post]
14 Dec 2021, 9:57 am by Dennis Crouch
  As you can see, this question attempts to tie the case directly to MedImmune, Inc. v. [read post]
7 Jun 2021, 6:36 am by Dennis Crouch
Genentech, Inc., 549 U.S. 118 (2007). [read post]
19 May 2021, 10:40 am by Dennis Crouch
Genentech, Inc., 549 U.S. 118 (2007); Cardinal Chem. [read post]
2 Jun 2020, 1:50 pm by Dennis Crouch
  Later, in MedImmune, Inc. v. [read post]
24 May 2018, 8:53 pm by Patent Docs
Noonan -- Ever since the Supreme Court loosened the reins on declaratory judgment actions in patent cases twelve years ago, in MedImmune v. [read post]
8 Sep 2016, 11:29 am by Dennis Crouch
The leading precedent actual-controversy precedent for patent cases is the Supreme Court’s 2007 decision in MedImmune, Inc. v. [read post]
13 Dec 2015, 7:55 am by Dennis Crouch
Zimmer, Inc., et al., Supreme Court Docket No. 14-1520 (2015). [3] Octane Fitness v. [read post]
6 Nov 2015, 6:58 am
  Therefore, it was not obvious to test pregabalin – it might be obvious to test gabapentin, but even here the judge considered that the skilled team would have little expectation of success.InsufficiencyAccording to the caselaw relating to sufficiency developed in MedImmune Ltd v Novartis Pharmaceuticals UK Ltd [2011] EWHC 1699 (Pat) at [458]-[484] and summarised in Sandvik Intellectual Property AB v Kennametal UK Ltd [2011] EWHC 3311 (Pat) at… [read post]